

Author index of volume 66

- Abe, N., see Hamaguchi, K. 66, 163
- Advani, A., Diabetic Complications: New Diagnostic Tools and Therapeutic Advances 66, 317
- Allen, E., see Warren, M.L. 66, 23
- Atik, U., see Eskandari, H.G. 66, 129
- Baik, S.H., see Choi, K.M. 66, 57
- Bajaj, S., see Sadikot, S.M. 66, 293
- Bajaj, S., see Sadikot, S.M. 66, 301
- Bajaj, S., see Sadikot, S.M. 66, 309
- Balamurugan, A.N., B. Ramakrishna, S. Gunasekaran, Insulin secretory characteristics of monkey pancreatic islets: a simple method of islet isolation and the effect of various density gradients on separation 66, 13
- Bandyopadhyay, S., see Sadikot, S.M. 66, 293
- Bandyopadhyay, S., see Sadikot, S.M. 66, 301
- Bandyopadhyay, S., see Sadikot, S.M. 66, 309
- Bashir, M.I., see Zargar, A.H. 66, 139
- Belfiglio, M., see Franciosi, M. 66, 277
- Bhat, M.H., see Zargar, A.H. 66, 139
- Bogoev, M., see Rašlová, K. 66, 193
- Bouma, J., see Keers, J.C. 66, 157
- Bradley, C., see Riaz, A. 66, 237
- Butler, C.L., see Dempsey, J.C. 66, 203
- Chan, W.B., G.T.C. Ko, V.T.F. Yeung, R. Osaki, R.C.W. Ma, W.Y. So, C.C. Chow, A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients 66, 97
- Chase, H.P., see Garg, S.K. 66, 49
- Chen, H.-D., see Pei, D. 66, 253
- Chen, X., H. Tian, R. Liu, Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients 66, 41
- Cheung, N.W., Is parity associated with earlier diagnosis of type 2 diabetes? 66, 287
- Chistiakov, D.A., K.V. Savost'anov, M.V. Shestakova, L.A. Chugunova, M.S. Samkhalova, I.I. Dedov, V.V. Nosikov, Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23–q24 by association study in Russian type 1 diabetic patients 66, 79
- Cho, Y.D., see Lee, G.T. 66, 119
- Choi, D.S., see Choi, K.M. 66, 57
- Choi, K.M., K.W. Lee, J.A. Seo, J.H. Oh, S.G. Kim, N.H. Kim, D.S. Choi, S.H. Baik, Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome 66, 57
- Chow, C.C., 66, 107
- Chow, C.C., see Chan, W.B. 66, 97
- Chugunova, L.A., see Chistiakov, D.A. 66, 79
- Cimen, M.Y.B., see Eskandari, H.G. 66, 129
- Conway, M.J., see Warren, M.L. 66, 23
- Dar, F.A., see Zargar, A.H. 66, 139
- Das, S., see Sadikot, S.M. 66, 293
- Das, S., see Sadikot, S.M. 66, 301
- Das, S., see Sadikot, S.M. 66, 309
- De Berardis, G., see Franciosi, M. 66, 277
- Dedov, I.I., see Chistiakov, D.A. 66, 79
- Dempsey, J.C., C.L. Butler, T.K. Sorensen, I.-M. Lee, M.L. Thompson, R.S. Miller, I.O. Frederick, M.A. Williams, A case-control study of maternal recreational physical activity and risk of gestational diabetes mellitus 66, 203
- Di Nardo, B., see Franciosi, M. 66, 277
- Dora, M., see Sadikot, S.M. 66, 293
- Dora, M., see Sadikot, S.M. 66, 301
- Dora, M., see Sadikot, S.M. 66, 309
- D'Souza, A., see Garg, S.K. 66, 49
- Egashira, T., see Tokuyama, Y. 66, 63
- Eskandari, H.G., M.Y.B. Cimen, L. Tamer, A. Kanik, U. Atik, Short term effects of L-carnitine on serum lipids in STZ-induced diabetic rats 66, 129
- Fang, S.C., see Pei, D. 66, 253
- Franciosi, M., F. Pellegrini, G. De Berardis, M. Belfiglio, B. Di Nardo, S. Greenfield, S.H. Kaplan, M. Sacco, G. Tognoni, M. Valentini, A. Nicolucci, The QUED Study Group, Correlates of satisfaction for the relationship with their physician in type 2 diabetic patients 66, 277
- Frederick, I.O., see Dempsey, J.C. 66, 203
- Fu, C.-C., see Pei, D. 66, 253
- Fu, H.-J., see Wang, J.-J. 66, 183
- Funatsu, H., H. Yamashita, E. Shimizu, T. Mimura, S. Nakamura, S. Hori, Quantitative measurement of retinal thickness in patients with diabetic macular edema is useful for evaluation of therapeutic agents 66, 219

- Gall, M.-A., see Rašlová, K. 66, 193
 Gans, R.O.B., see Keers, J.C. 66, 157
 Garg, S.K., P.A. Gottlieb, M.E. Hisatomi, A. D'Souza, A.J. Walker, K.E. Izuora, H.P. Chase, Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine 66, 49
 Goenka, K., see Sadikot, S.M. 66, 293
 Goenka, K., see Sadikot, S.M. 66, 309
 Gomes, M.B., V.G. Nogueira, Acute-phase proteins and microalbuminuria among patients with type 2 diabetes 66, 31
 Gottlieb, P.A., see Garg, S.K. 66, 49
 Greenfield, S., see Franciosi, M. 66, 277
 Guan, J.Z., see Matsui, J. 66, 229
 Gunasekaran, S., see Balamurugan, A.N. 66, 13
- Haas, M.J., see Horani, M.H. 66, 7
 Hamaguchi, K., A. Kimura, Y. Kusuda, T. Yamashita, M. Yasunami, M. Takahashi, N. Abe, H. Yoshimatsu, Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes 66, 163
 Hâncu, N., see Rašlová, K. 66, 193
 Haneda, M., R. Kikkawa, H. Sakai, R. Kawamori, Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy 66, 87
 Hatazaki, M., see Nakahara, I. 66, 109
 Hayashi, C., O. Ogawa, S. Kubo, N. Mitsuhashi, T. Onuma, R. Kawamori, Ankle brachial pressure index and carotid intima-media thickness as atherosclerosis markers in Japanese diabetics 66, 269
 Hazra, D.K., see Sadikot, S.M. 66, 293
 Hazra, D.K., see Sadikot, S.M. 66, 301
 Hazra, D.K., see Sadikot, S.M. 66, 309
 Hisatomi, M.E., see Garg, S.K. 66, 49
 Horani, M.H., M.J. Haas, A.D. Mooradian, Rapid adaptive down regulation of oxidative burst induced by high dextrose in human umbilical vein endothelial cells 66, 7
 Hori, M., see Nakahara, I. 66, 109
 Hori, S., see Funatsu, H. 66, 219
 Hsiao, C.-F., see Pei, D. 66, 253
 Hsu, W.-L., see Pei, D. 66, 253
 Hu, G., see Wang, J.-J. 66, 183
 Hung, Y.-J., see Pei, D. 66, 253
- Ishizuka, T., see Tokuyama, Y. 66, 63
 Izuora, K.E., see Garg, S.K. 66, 49
- Jain, S., see Sadikot, S.M. 66, 293
 Jain, S., see Sadikot, S.M. 66, 301
 Jain, S., see Sadikot, S.M. 66, 309
 Jamal, A., see Sadikot, S.M. 66, 293
 Jamal, A., see Sadikot, S.M. 66, 301
 Jamal, A., see Sadikot, S.M. 66, 309
 Jena, B., see Sadikot, S.M. 66, 293
 Jena, B., see Sadikot, S.M. 66, 301
 Jena, B., see Sadikot, S.M. 66, 309
- Kajimoto, Y., see Nakahara, I. 66, 109
 Kanatsuka, A., see Tokuyama, Y. 66, 63
 Kanik, A., see Eskandari, H.G. 66, 129
 Kaplan, S.H., see Franciosi, M. 66, 277
 Kasai, N., see Matsui, J. 66, 229
 Kato, S., see Takayanagi, N. 66, 245
 Kawamori, R., see Haneda, M. 66, 87
 Kawamori, R., see Hayashi, C. 66, 269
 Kawamori, R., see Takayanagi, N. 66, 245
 Keers, J.C., T.P. Links, J. Bouma, R.O.B. Gans, J.C. ter Maaten, B.H.R. Wolffenbuttel, W.J. Sluiter, R. Sanderman, Do diabetologists recognise self-management problems in their patients? 66, 157
 Kikkawa, R., see Haneda, M. 66, 87
 Kim, N.H., see Choi, K.M. 66, 57
 Kim, S.G., see Choi, K.M. 66, 57
 Kimura, A., see Hamaguchi, K. 66, 163
 Klaff, L.J., see Warren, M.L. 66, 23
 Ko, G.T.C., see Chan, W.B. 66, 97
 Komatsu, R., see Ohara, S. 66, 133
 Kubo, S., see Hayashi, C. 66, 269
 Kubota, M., see Nakahara, I. 66, 109
 Kuo, S.-W., see Pei, D. 66, 253
 Kuroda, A., see Nakahara, I. 66, 109
 Kusuda, Y., see Hamaguchi, K. 66, 163
- Laway, B.A., see Zargar, A.H. 66, 139
 Lee, G.T., Y.D. Cho, Regulation of fibronectin levels by agmatine and spermine in mesangial cells under high-glucose conditions 66, 119
 Lee, I.-M., see Dempsey, J.C. 66, 203
 Lee, K.W., see Choi, K.M. 66, 57
 Leth, G., see Rašlová, K. 66, 193
 Li, H.-B., see Wang, J.-J. 66, 183
 Lian, W.-C., see Pei, D. 66, 253
 Links, T.P., see Keers, J.C. 66, 157
 Liu, R., see Chen, X. 66, 41
 Ludvigsson, J., see Samuelsson, U. 66, 173
 Lunt, H., see Wilson, M. 66, 263
- Ma, R.C.W., see Chan, W.B. 66, 97
 Masoodi, S.R., see Zargar, A.H. 66, 139
 Matsuhisa, M., see Nakahara, I. 66, 109
 Matsui, J., N. Tamasawa, J. Tanabe, N. Kasai, H. Murakami, K. Yamato, J.Z. Guan, T. Suda, LDL particle size and lipid composition are risk factors for microalbuminuria in normotensive and normocholesterolemic patients with type 2 diabetes 66, 229
 Matsui, K., see Tokuyama, Y. 66, 63
 Matsuyama, T., see Ohara, S. 66, 133
 Metcalf, P., see Scragg, R. 66, 147
 Miller, R.S., see Dempsey, J.C. 66, 203
 Mimura, T., see Funatsu, H. 66, 219
 Mishra, R., see Sadikot, S.M. 66, 293
 Mishra, R., see Sadikot, S.M. 66, 301
 Mishra, R., see Sadikot, S.M. 66, 309
 Mitsuhashi, N., see Hayashi, C. 66, 269
 Mooradian, A.D., see Horani, M.H. 66, 7

- Moore, M.P., see Wilson, M. 66, 263
- Mukherjee, S., see Sadikot, S.M. 66, 293
- Mukherjee, S., see Sadikot, S.M. 66, 301
- Mukherjee, S., see Sadikot, S.M. 66, 309
- Munichoodappa, C., see Sadikot, S.M. 66, 293
- Munichoodappa, C., see Sadikot, S.M. 66, 301
- Munichoodappa, C., see Sadikot, S.M. 66, 309
- Murakami, H., see Matsui, J. 66, 229
- Murthy, S.S., see Sadikot, S.M. 66, 293
- Murthy, S.S., see Sadikot, S.M. 66, 301
- Murthy, S.S., see Sadikot, S.M. 66, 309
- Nabavizadeh Rafsanjani, F., J. Vahedian, The effect of insulin-dependent diabetes mellitus on basal and distention-induced acid and pepsin secretion in rat 66, 1
- Nakahara, I., M. Matsuhisa, Y. Shiba, A. Kuroda, Y. Nakatani, M. Hatazaki, Y. Kajimoto, M. Kubota, Y. Yamasaki, M. Hori, Acute elevation of free fatty acids impairs hepatic glucose uptake in conscious rats 66, 109
- Nakamura, S., see Funatsu, H. 66, 219
- Nakatani, Y., see Nakahara, I. 66, 109
- Nicolucci, A., see Franciosi, M. 66, 277
- Nigam, A., see Sadikot, S.M. 66, 293
- Nigam, A., see Sadikot, S.M. 66, 301
- Nigam, A., see Sadikot, S.M. 66, 309
- Nishiyama, K., see Takayanagi, N. 66, 245
- Nogueira, V.A.A.C.A.G., see Gomes, M.A.A.C.A.B. 66, 31
- Nomiyama, T., see Takayanagi, N. 66, 245
- Nosikov, V.V., see Chistiakov, D.A. 66, 79
- Nozaki, O., see Tokuyama, Y. 66, 63
- Ogawa, O., see Hayashi, C. 66, 269
- Oh, J.H., see Choi, K.M. 66, 57
- Ohara, S., R. Komatsu, T. Matsuyama, Short-term effect of buformin, a biguanide, on insulin sensitivity, soluble fraction of tumor necrosis factor receptor and serum lipids in overweight patients with type 2 diabetes mellitus 66, 133
- Onuma, T., see Hayashi, C. 66, 269
- Onuma, T., see Takayanagi, N. 66, 245
- Osaki, R., see Chan, W.B. 66, 97
- Padaiga, Z., see Samuelsson, U. 66, 173
- Patra Goenka, P., see Sadikot, S.M. 66, 293
- Patra, P., see Sadikot, S.M. 66, 301
- Patra, P., see Sadikot, S.M. 66, 309
- Pei, D., Y.-J. Hung, H.-D. Chen, C.-F. Hsiao, C.-C. Fu, T.-C. Yang, W.-C. Lian, S.C. Fang, W.-L. Hsu, S.-W. Kuo, The insulin sensitivity, glucose effectiveness and acute insulin response to glucose load of non-obese adolescent type 2 diabetes 66, 253
- Pellegrini, F., see Franciosi, M. 66, 277
- Pickup, J., see Riazzi, A. 66, 237
- Prasannakumar, K.M., see Sadikot, S.M. 66, 293
- Prasannakumar, K.M., see Sadikot, S.M. 66, 301
- Prasannakumar, K.M., see Sadikot, S.M. 66, 309
- Ramakrishna, B., see Balamurugan, A.N. 66, 13
- Rašlová, K., M. Bogoev, I. Raz, G. Leth, M.-A. Gall, N. Hâncu, Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes 66, 193
- Raz, I., see Rašlová, K. 66, 193
- Riazzi, A., J. Pickup, C. Bradley, Daily stress and glycaemic control in Type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity 66, 237
- Rosenstock, J., see Warren, M.L. 66, 23
- Sacco, M., see Franciosi, M. 66, 277
- Sadasivrao, Y., see Sadikot, S.M. 66, 293
- Sadasivrao, Y., see Sadikot, S.M. 66, 301
- Sadasivrao, Y., see Sadikot, S.M. 66, 309
- Sadauskaite, V., see Samuelsson, U. 66, 173
- Sadikot, S.M., A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra, K. Goenka, The burden of diabetes and impaired fasting glucose in India using the ADA 1997 criteria: prevalence of diabetes in India study (PODIS) 66, 293
- S.M. Sadikot, A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra Goenka, The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS) 66, 301
- S.M. Sadikot, A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra, K. Goenka, Comparing the ADA 1997 and the WHO 1999 criteria: Prevalence of Diabetes in India Study 66, 309
- Sai, K., see Sadikot, S.M. 66, 301
- Sai, K., see Sadikot, S.M. 66, 309
- Sakai, H., see Haneda, M. 66, 87
- Samkhalova, M.S., see Chistiakov, D.A. 66, 79
- Samuelsson, U., V. Sadauskaite, Z. Padaiga, J. Ludvigsson, DEBA Study Group, A fourfold difference in the incidence of type 1 diabetes between Sweden and Lithuania but similar prevalence of autoimmunity 66, 173
- Sanderman, R., see Keers, J.C. 66, 157
- Savost'anov, K.V., see Chistiakov, D.A. 66, 79
- Scragg, R., P. Metcalf, Do triglycerides explain the U-shaped relation between alcohol and diabetes risk? Results from a cross-sectional survey of alcohol and plasma glucose 66, 147
- Seo, J.A., see Choi, K.M. 66, 57
- Seshiah, V., see Sadikot, S.M. 66, 293
- Seshiah, V., see Sadikot, S.M. 66, 301
- Seshiah, V., see Sadikot, S.M. 66, 309
- Sheikh, M.I., see Zargar, A.H. 66, 139
- Shestakova, M.V., see Chistiakov, D.A. 66, 79
- Shiba, Y., see Nakahara, I. 66, 109
- Shimizu, E., see Funatsu, H. 66, 219
- Singh, S.K., see Sadikot, S.M. 66, 293

- Singh, S.K., see Sadikot, S.M. 66, 301
Singh, S.K., see Sadikot, S.M. 66, 309
Sinha, N.K., see Sadikot, S.M. 66, 293
Sinha, N.K., see Sadikot, S.M. 66, 301
Sinha, N.K., see Sadikot, S.M. 66, 309
Sluiter, W.J., see Keers, J.C. 66, 157
So, W.Y., see Chan, W.B. 66, 97
Sorensen, T.K., see Dempsey, J.C. 66, 203
Sosale, A., see Sadikot, S.M. 66, 293
Sosale, A., see Sadikot, S.M. 66, 301
Sosale, A., see Sadikot, S.M. 66, 309
Suda, T., see Matsui, J. 66, 229

Takahasi, M., see Hamaguchi, K. 66, 163
Takayanagi, N., T. Onuma, S. Kato, K. Nishiyama, T. Nomiyama, R. Kawamori, Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients 66, 245
Tamasawa, N., see Matsui, J. 66, 229
Tamer, L., see Eskandari, H.G. 66, 129
Tan, M.Y., The relationship of health beliefs and complication prevention behaviors of Chinese individuals with Type 2 Diabetes Mellitus 66, 71
Tanabe, J., see Matsui, J. 66, 229
ter Maaten, J.C., see Keers, J.C. 66, 157
Thompson, M.L., see Dempsey, J.C. 66, 203
Tian, H., see Chen, X. 66, 41
Tognoni, G., see Franciosi, M. 66, 277
Tokuyama, Y., K. Matsui, T. Egashira, O. Nozaki, T. Ishizuka, A. Kanatsuka, Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population 66, 63
Tuomilehto, J., see Wang, J.-J. 66, 183

Vahedian, J., see Nabavizadeh Rafsanjani, F. 66, 1

Valentini, M., see Franciosi, M. 66, 277

Walker, A.J., see Garg, S.K. 66, 49
Wang, J.-J., S.-Y. Yuan, L.-X. Zhu, H.-J. Fu, H.-B. Li, G. Hu, J. Tuomilehto, Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose 66, 183
Wani, A.I., see Zargar, A.H. 66, 139
Warren, M.L., M.J. Conway, L.J. Klaff, J. Rosenstock, E. Allen, Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients 66, 23
Williams, M.A., see Dempsey, J.C. 66, 203
Wilson, M., M.P. Moore, H. Lunt, Treatment satisfaction after commencement of insulin in Type 2 diabetes 66, 263
Wolffenbuttel, B.H.R., see Keers, J.C. 66, 157

Yamasaki, Y., see Nakahara, I. 66, 109
Yamashita, H., see Funatsu, H. 66, 219
Yamashita, T., see Hamaguchi, K. 66, 163
Yamato, K., see Matsui, J. 66, 229
Yang, T.-C., see Pei, D. 66, 253
Yasunami, M., see Hamaguchi, K. 66, 163
Yeung, V.T.F., see Chan, W.B. 66, 97
Yoshimatsu, H., see Hamaguchi, K. 66, 163
Yuan, S.-Y., see Wang, J.-J. 66, 183

Zargar, A.H., M.I. Sheikh, M.I. Bashir, S.R. Masoodi, B.A. Laway, A.I. Wani, M.H. Bhat, F.A. Dar, Prevalence of gestational diabetes mellitus in Kashmiri women from the Indian subcontinent 66, 139
Zargar, A.H., see Sadikot, S.M. 66, 293
Zargar, A.H., see Sadikot, S.M. 66, 301
Zargar, A.H., see Sadikot, S.M. 66, 309
Zhu, L.-X., see Wang, J.-J. 66, 183

Subject index of volume 66

A1C values; Insulin glargine; Morning, evening, or split dose glargine treatment; Type 1 diabetes; Severe hypoglycemic episodes **66**, 49

Acute insulin response after glucose load; Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Glucose effectiveness **66**, 253

Acute-phase proteins; Microalbuminuria; Type 2 diabetes **66**, 31

ADA 1997; Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; WHO 1999; Prevalence; India; Urban; Rural **66**, 309

Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Glucose effectiveness; Acute insulin response after glucose load **66**, 253

Agmatine; Spermine; TGF- β 1; ERK; Fibronectin **66**, 119

Alcohol; Diabetes; Glucose; Serum triglycerides **66**, 147

Angiotensin II receptor blocker; Type 2 diabetes; Proteinuria; Candesartan **66**, 87

Angiotensin-converting enzyme inhibitor; Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Diabetic macular edema; Vascular permeability **66**, 219

Ankle brachial pressure index; Carotid intima-media thickness; Cardiovascular disease; Type 2 diabetes **66**, 269

Ankle-brachial pressure index; Type 2 diabetes; Metabolic syndrome; Pulse wave velocity **66**, 57

Antioxidants; Oxidation; Hyperglycemia; Diabetes **66**, 7

Apolipoprotein C III; Type 2 diabetes mellitus; Sst I polymorphism; Carotid intima-media thickness **66**, 41

Autoimmune disorders; Type 1 diabetes; Environmental factors; Inheritance factors **66**, 173

Biguanide; Insulin sensitivity; Glucose clamp; TNF- α ; Buformin **66**, 133

Biphasic insulin aspart; Postprandial dosing; Type 2 diabetes **66**, 23

Buformin; Biguanide; Insulin sensitivity; Glucose clamp; TNF- α **66**, 133

C-peptide; Glutamic acid decarboxylase (GAD); HLA; Type 2 diabetes; Polymorphism **66**, 163

Candesartan; Type 2 diabetes; Proteinuria; Angiotensin II receptor blocker **66**, 87

Cardiovascular disease; Ankle brachial pressure index; Carotid intima-media thickness; Type 2 diabetes **66**, 269

L-Carnitine; Streptozotocin; Diabetes; Triglycerides; Total cholesterol **66**, 129

Carotid intima-media thickness; Ankle brachial pressure index; Cardiovascular disease; Type 2 diabetes **66**, 269

Carotid intima-media thickness; Type 2 diabetes mellitus; Apolipoprotein C III; Sst I polymorphism **66**, 41

Chromosome 3q23–q24; Diabetic nephropathy; Susceptibility locus; Type 1 diabetes mellitus; Russian population **66**, 79

Complication preventive behavior; Health beliefs; Diabetes complications; Type 2 Diabetes **66**, 71

Daily hassles; Type 1 diabetes; Stress; Individual differences **66**, 237

Dense LDL; Type 2 diabetes mellitus; Small; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245

- Diabetes complications;** Health beliefs; Complication preventive behavior; Type 2 Diabetes **66**, 71
- Diabetes mellitus;** Parity; Pregnancy **66**, 287
- Diabetes;** L-Carnitine; Streptozotocin; Triglycerides; Total cholesterol **66**, 129
- Diabetes;** Alcohol; Glucose; Serum triglycerides **66**, 147
- Diabetes;** Gastric acid; Gastric pepsin; Distension; Rat **66**, 1
- Diabetes;** Oxidation; Antioxidants; Hyperglycemia **66**, 7
- Diabetic macular edema;** Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- Diabetic nephropathy;** Chromosome 3q23-q24; Susceptibility locus; Type 1 diabetes mellitus; Russian population **66**, 79
- Diabetologists;** Distress; Medical decision-making; Referral **66**, 157
- Distension;** Diabetes; Gastric acid; Gastric pepsin; Rat **66**, 1
- Distress;** Diabetologists; Medical decision-making; Referral **66**, 157
- Endogenous glucose production;** FFA; Hepatic glucose uptake **66**, 109
- Environmental factors;** Type 1 diabetes; Autoimmune disorders; Inheritance factors **66**, 173
- ERK;** Agmatine; Spermine; TGF- β 1; Fibronectin **66**, 119
- Evaluation of therapeutic agent;** Quantitative measurement of macular thickness; Diabetic macular edema; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- FFA;** Hepatic glucose uptake; Endogenous glucose production **66**, 109
- Fibronectin;** Agmatine; Spermine; TGF- β 1; ERK **66**, 119
- Follow-up;** Type 2 diabetes; IFG; IGT; Predictor **66**, 183
- Frequent-sampled intravenous glucose tolerance test;** Adolescent type 2 diabetes; Insulin resistance; Glucose effectiveness; Acute insulin response after glucose load **66**, 253
- Gastric acid;** Diabetes; Gastric pepsin; Distension; Rat **66**, 1
- Gastric pepsin;** Diabetes; Gastric acid; Distension; Rat **66**, 1
- Gestational diabetes mellitus;** Glucose challenge test; Glucose tolerance test; Prevalence **66**, 139
- Gestational diabetes;** Physical activity; Pregnancy **66**, 203
- Glucagon-like peptide-1 receptor;** Glucagon-like peptide-1; Type 2 diabetes; Missense mutation; Minimal model analysis **66**, 63
- Glucagon-like peptide-1;** Glucagon-like peptide-1 receptor; Type 2 diabetes; Missense mutation; Minimal model analysis **66**, 63
- Glucose challenge test;** Gestational diabetes mellitus; Glucose tolerance test; Prevalence **66**, 139
- Glucose clamp;** Biguanide; Insulin sensitivity; TNF- α ; Buformin **66**, 133
- Glucose effectiveness;** Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Acute insulin response after glucose load **66**, 253
- Glucose tolerance test;** Gestational diabetes mellitus; Glucose challenge test; Prevalence **66**, 139
- Glucose;** Alcohol; Diabetes; Serum triglycerides **66**, 147
- Glutamic acid decarboxylase (GAD);** HLA; Type 2 diabetes; Polymorphism; C-peptide **66**, 163
- Gradient separation;** Monkey islet; Insulin secretion; Secretagogues; Stimulation index **66**, 13
- Health beliefs;** Diabetes complications; Complication preventive behavior; Type 2 Diabetes **66**, 71
- Hepatic glucose uptake;** FFA; Endogenous glucose production **66**, 109
- HLA;** Glutamic acid decarboxylase (GAD); Type 2 diabetes; Polymorphism; C-peptide **66**, 163

- Hyperglycemia**; Oxidation; Antioxidants; Diabetes **66**, 7
- IFG**; Type 2 diabetes; Follow-up; IGT; Predictor **66**, 183
- IGT**; Type 2 diabetes; Follow-up; IFG; Predictor **66**, 183
- Impaired fasting glucose**; Type 2 diabetes; Impaired glucose tolerance; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- Impaired fasting glucose**; Type 2 diabetes; Prevalence; Urban; Rural; India **66**, 293
- Impaired glucose tolerance (IGT)**; Type 2 diabetes; Prevalence; Urban India; Rural India **66**, 301
- Impaired glucose tolerance**; Type 2 diabetes; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- India**; Type 2 diabetes; Impaired fasting glucose; Prevalence; Urban; Rural **66**, 293
- India**; Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; Urban; Rural **66**, 309
- Individual differences**; Type 1 diabetes; Stress; Daily hassles **66**, 237
- Inheritance factors**; Type 1 diabetes; Autoimmune disorders; Environmental factors **66**, 173
- Insulin aspart**; Type 2 diabetes; Insulin detemir; Weight; Variation in FPG **66**, 193
- Insulin detemir**; Type 2 diabetes; Insulin aspart; Weight; Variation in FPG **66**, 193
- Insulin glargine**; Morning, evening, or split dose glargine treatment; Type 1 diabetes; Severe hypoglycemic episodes; A1C values **66**, 49
- Insulin resistance**; Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Glucose effectiveness; Acute insulin response after glucose load **66**, 253
- Insulin secretion**; Monkey islet; Gradient separation; Secretagogues; Stimulation index **66**, 13
- Insulin sensitivity**; Biguanide; Glucose clamp; TNF- α ; Buformin **66**, 133
- Insulin treatment**; Type 2 diabetes; Treatment satisfaction; Well-being **66**, 263
- Medical decision-making**; Diabetologists; Distress; Referral **66**, 157
- Metabolic syndrome**; Type 2 diabetes; Pulse wave velocity; Ankle-brachial pressure index **66**, 57
- Microalbuminuria**; Acute-phase proteins; Type 2 diabetes **66**, 31
- Microalbuminuria**; Small dense LDL; α -Tocopherol; Oxidation; Type 2 diabetes mellitus **66**, 229
- Minimal model analysis**; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Type 2 diabetes; Missense mutation **66**, 63
- Missense mutation**; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Type 2 diabetes; Minimal model analysis **66**, 63
- Monkey islet**; Insulin secretion; Gradient separation; Secretagogues; Stimulation index **66**, 13
- Morning, evening, or split dose glargine treatment**; Insulin glargine; Type 1 diabetes; Severe hypoglycemic episodes; A1C values **66**, 49
- Oxidation**; Antioxidants; Hyperglycemia; Diabetes **66**, 7
- Oxidation**; Small dense LDL; Microalbuminuria; α -Tocopherol; Type 2 diabetes mellitus **66**, 229
- Parity**; Diabetes mellitus; Pregnancy **66**, 287
- Patient satisfaction**; Type 2 diabetes; Quality of life; Patient-doctor relationship; Questionnaire **66**, 277
- Patient-doctor relationship**; Type 2 diabetes; Patient satisfaction; Quality of life; Questionnaire **66**, 277
- Physical activity**; Gestational diabetes; Pregnancy **66**, 203
- Polymorphism**; Glutamic acid decarboxylase (GAD); HLA; Type 2 diabetes; C-peptide **66**, 163
- Postprandial dosing**; Biphasic insulin aspart; Type 2 diabetes **66**, 23

- Postprandial lipoprotein metabolism;** Type 2 diabetes mellitus; Small; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP) **66**, 245
- Predictor;** Type 2 diabetes; Follow-up; IFG; IGT **66**, 183
- Pregnancy;** Diabetes mellitus; Parity **66**, 287
- Pregnancy;** Gestational diabetes; Physical activity **66**, 203
- Prevalence;** Gestational diabetes mellitus; Glucose challenge test; Glucose tolerance test **66**, 139
- Prevalence;** Type 2 diabetes; Impaired fasting glucose; Urban; Rural; India **66**, 293
- Prevalence;** Type 2 diabetes; Impaired glucose tolerance (IGT); Urban India; Rural India **66**, 301
- Prevalence;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; India; Urban; Rural **66**, 309
- Proteinuria;** Type 2 diabetes; Candesartan; Angiotensin II receptor blocker **66**, 87
- Pulse wave velocity;** Type 2 diabetes; Metabolic syndrome; Ankle-brachial pressure index **66**, 57
- Quality of life;** Type 2 diabetes; Patient satisfaction; Patient-doctor relationship; Questionnaire **66**, 277
- Quantitative measurement of macular thickness;** Evaluation of therapeutic agent; Diabetic macular edema; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- Questionnaire;** Type 2 diabetes; Patient satisfaction; Quality of life; Patient-doctor relationship **66**, 277
- Rat;** Diabetes; Gastric acid; Gastric pepsin; Distension **66**, 1
- Referral;** Diabetologists; Distress; Medical decision-making **66**, 157
- Remnant lipoproteins;** Type 2 diabetes mellitus; Small; Dense LDL; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Remnant-like particles (RLP);** Type 2 diabetes mellitus; Small; Dense LDL; Remnant lipoproteins; Postprandial lipoprotein metabolism **66**, 245
- Rural India;** Type 2 diabetes; Impaired glucose tolerance (IGT); Prevalence; Urban India **66**, 301
- Rural;** Type 2 diabetes; Impaired fasting glucose; Prevalence; Urban; India **66**, 293
- Rural;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban **66**, 309
- Russian population;** Chromosome 3q23-q24; Diabetic nephropathy; Susceptibility locus; Type 1 diabetes mellitus **66**, 79
- Secretagogues;** Monkey islet; Insulin secretion; Gradient separation; Stimulation index **66**, 13
- Serum triglycerides;** Alcohol; Diabetes; Glucose **66**, 147
- Severe hypoglycemic episodes;** Insulin glargine; Morning, evening, or split dose glargine treatment; Type 1 diabetes; A1C values **66**, 49
- Small dense LDL;** Microalbuminuria; α -Tocopherol; Oxidation; Type 2 diabetes mellitus **66**, 229
- Small;** Type 2 diabetes mellitus; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Spermine;** Agmatine; TGF- β 1; ERK; Fibronectin **66**, 119
- Sst I polymorphism;** Type 2 diabetes mellitus; Apolipoprotein C III; Carotid intima-media thickness **66**, 41
- Stimulation index;** Monkey islet; Insulin secretion; Gradient separation; Secretagogues **66**, 13
- Streptozotocin;** L-Carnitine; Diabetes; Triglycerides; Total cholesterol **66**, 129
- Stress;** Type 1 diabetes; Daily hassles; Individual differences **66**, 237
- Susceptibility locus;** Chromosome 3q23-q24; Diabetic nephropathy; Type 1 diabetes mellitus; Russian population **66**, 79
- TGF- β 1;** Agmatine; Spermine; ERK; Fibronectin **66**, 119
- TNF- α ;** Biguanide; Insulin sensitivity; Glucose clamp; Buformin **66**, 133
- α -Tocopherol;** Small dense LDL; Microalbuminuria; Oxidation; Type 2 diabetes mellitus **66**, 229

- Total cholesterol**; L-Carnitine; Streptozotocin; Diabetes; Triglycerides **66**, 129
- Treatment satisfaction**; Type 2 diabetes; Insulin treatment; Well-being **66**, 263
- Triglycerides**; L-Carnitine; Streptozotocin; Diabetes; Total cholesterol **66**, 129
- Type 1 diabetes mellitus**; Chromosome 3q23-q24; Diabetic nephropathy; Susceptibility locus; Russian population **66**, 79
- Type 1 diabetes**; Autoimmune disorders; Environmental factors; Inheritance factors **66**, 173
- Type 1 diabetes**; Insulin glargine; Morning, evening, or split dose glargine treatment; Severe hypoglycemic episodes; A1C values **66**, 49
- Type 1 diabetes**; Stress; Daily hassles; Individual differences **66**, 237
- Type 2 diabetes mellitus**; Apolipoprotein C III; Sst I polymorphism; Carotid intima-media thickness **66**, 41
- Type 2 diabetes mellitus**; Small dense LDL; Microalbuminuria; α -Tocopherol; Oxidation **66**, 229
- Type 2 diabetes mellitus**; Small; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Type 2 diabetes**; Acute-phase proteins; Microalbuminuria **66**, 31
- Type 2 diabetes**; Ankle brachial pressure index; Carotid intima-media thickness; Cardiovascular disease **66**, 269
- Type 2 diabetes**; Biphasic insulin aspart; Postprandial dosing **66**, 23
- Type 2 diabetes**; Follow-up; IFG; IGT; Predictor **66**, 183
- Type 2 diabetes**; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Missense mutation; Minimal model analysis **66**, 63
- Type 2 diabetes**; Glutamic acid decarboxylase (GAD); HLA; Polymorphism; C-peptide **66**, 163
- Type 2 Diabetes**; Health beliefs; Diabetes complications; Complication preventive behavior **66**, 71
- Type 2 diabetes**; Impaired fasting glucose; Prevalence; Urban; Rural; India **66**, 293
- Type 2 diabetes**; Impaired glucose tolerance (IGT); Prevalence; Urban India; Rural India **66**, 301
- Type 2 diabetes**; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- Type 2 diabetes**; Insulin detemir; Insulin aspart; Weight; Variation in FPG **66**, 193
- Type 2 diabetes**; Insulin treatment; Treatment satisfaction; Well-being **66**, 263
- Type 2 diabetes**; Metabolic syndrome; Pulse wave velocity; Ankle-brachial pressure index **66**, 57
- Type 2 diabetes**; Patient satisfaction; Quality of life; Patient-doctor relationship; Questionnaire **66**, 277
- Type 2 diabetes**; Proteinuria; Candesartan; Angiotensin II receptor blocker **66**, 87
- Urban India**; Type 2 diabetes; Impaired glucose tolerance (IGT); Prevalence; Rural India **66**, 301
- Urban**; Type 2 diabetes; Impaired fasting glucose; Prevalence; Rural; India **66**, 293
- Urban**; Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Rural **66**, 309
- Variation in FPG**; Type 2 diabetes; Insulin detemir; Insulin aspart; Weight **66**, 193
- Vascular permeability**; Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Diabetic macular edema; Angiotensin-converting enzyme inhibitor **66**, 219
- Weight**; Type 2 diabetes; Insulin detemir; Insulin aspart; Variation in FPG **66**, 193
- Well-being**; Type 2 diabetes; Insulin treatment; Treatment satisfaction **66**, 263
- WHO 1999**; Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; Prevalence; India; Urban; Rural **66**, 309

